DDInter704 DDInter119
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Everolimus {u} (Compound) resembles {v} (Compound) Pimecrolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Everolimus {u} (Compound) treats {v} (Disease) kidney cancer
Everolimus {u} (Compound) binds {v} (Gene) FKBP1A
Everolimus {u} (Compound) upregulates {v} (Gene) USP20
Everolimus {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2D6 Inhibitors
Everolimus {u} (Compound) downregulates {v} (Gene) ATF1
Everolimus {u} (Compound) causes {v} (Side Effect) Pericardial effusion
Everolimus (Compound) resembles Pimecrolimus (Compound)
Everolimus (Compound) resembles Temsirolimus (Compound)
Everolimus (Compound) treats kidney cancer (Disease)
Everolimus (Compound) binds FKBP1A (Gene)
Everolimus (Compound) upregulates USP20 (Gene)
Everolimus (Compound) is included by Cytochrome P450 2D6 Inhibitors (Pharmacologic Class)
Everolimus (Compound) downregulates ATF1 (Gene)
Everolimus (Compound) causes Pericardial effusion (Side Effect)